On May 29, Illumina rose 5.09% in regular trading, trading at $157.87/share, with trading volume of $142 million. The move was driven by the company's announcement of its first distributed whole-genome sequencing solution for high-sensitivity molecular residual disease (MRD) research.

The new workflow is designed to support residual disease detection and cancer genomic profiling using solid tumor and blood samples. According to the company, the workflow completes processing in approximately five days and targets analytical sensitivity down to 10 parts per million for certain tumors. Illumina's Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise. The company has opened early access to select clinical research partners and plans a broader commercial launch next year.

The broader Life Sciences Tools & Services sector also posted strong gains, with Agilent up 18.83%, Icon PLC up 14.86%, Tempus AI up 8.54%, Thermo Fisher Scientific up 6.69%, and Danaher up 3.97%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)